Description
Background:
Catumaxomab (Removab(), is a trifunctional IgG2 antibody approved for the treatment of malignant ascites (in 2009), a condition found in patients with a variety of epithelial cancers. It is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD3 receptors. It also has an intact immunoglobulin gamma constant region allowing it to bind to Fc_ I, IIa, and III receptors. By binding to CD3 on T cells, EpCAM on cancer cells, and Fc_ receptors on accessory immune cells like macrophages and NK cells, Catumaxomab brings immune cells into close proximity to EpCAM positive cancer cells. As a functional antibody, Catumaxomab also stimulates bound NK cells to release cytotoxic mediators like granzyme or bound macrophages to phagocytose the cancer cell.
Intended Use:
For Estimation of Catumaxomab (REMOVAB) in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!